DOP2012000158A - Derivados de sulfonamida heterociclicos - Google Patents
Derivados de sulfonamida heterociclicosInfo
- Publication number
- DOP2012000158A DOP2012000158A DO2012000158A DO2012000158A DOP2012000158A DO P2012000158 A DOP2012000158 A DO P2012000158A DO 2012000158 A DO2012000158 A DO 2012000158A DO 2012000158 A DO2012000158 A DO 2012000158A DO P2012000158 A DOP2012000158 A DO P2012000158A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- heterociclic
- sulfonamide derivatives
- compounds
- inflammation
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
Abstract
La presente invención se refiere a los compuestos de la fórmula (I): y a las sales farmacéuticamente aceptables de los mismos. Se ha demostrado que los compuestos son inhibidores de MEK y, por consiguiente, pueden ser útiles en el tratamiento de las enfermedades hiperproliferativas (por ejemplo, cáncer e inflamación).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN3019CH2009 | 2009-12-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2012000158A true DOP2012000158A (es) | 2012-09-30 |
Family
ID=43708813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2012000158A DOP2012000158A (es) | 2009-12-08 | 2012-06-08 | Derivados de sulfonamida heterociclicos |
Country Status (26)
Country | Link |
---|---|
US (1) | US8614239B2 (es) |
EP (1) | EP2509964B1 (es) |
JP (1) | JP5456908B2 (es) |
KR (1) | KR20120102750A (es) |
CN (1) | CN102648188A (es) |
AU (1) | AU2010329940B2 (es) |
BR (1) | BR112012013735A2 (es) |
CA (1) | CA2781218A1 (es) |
CL (1) | CL2012001485A1 (es) |
CO (1) | CO6551751A2 (es) |
CR (1) | CR20120311A (es) |
CU (1) | CU20120085A7 (es) |
DO (1) | DOP2012000158A (es) |
EA (1) | EA201200823A1 (es) |
EC (1) | ECSP12011984A (es) |
ES (1) | ES2484171T3 (es) |
GE (1) | GEP20135998B (es) |
GT (1) | GT201200183A (es) |
IL (1) | IL219635A0 (es) |
MA (1) | MA33848B1 (es) |
MX (1) | MX2012006561A (es) |
NI (1) | NI201200100A (es) |
PE (1) | PE20121384A1 (es) |
TN (1) | TN2012000242A1 (es) |
WO (1) | WO2011070030A1 (es) |
ZA (1) | ZA201203324B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2838029A1 (en) * | 2011-06-09 | 2012-12-13 | Novartis Ag | Heterocyclic sulfonamide derivatives |
CN103748085A (zh) * | 2011-06-09 | 2014-04-23 | 诺华股份有限公司 | 杂环磺酰胺衍生物 |
WO2013001372A2 (en) * | 2011-06-30 | 2013-01-03 | University Of Oslo | Methods and compositions for inhibition of activation of regulatory t cells |
CN103204822B (zh) | 2012-01-17 | 2014-12-03 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的苯并噁唑化合物及其制备方法和用途 |
US9657013B2 (en) * | 2012-02-29 | 2017-05-23 | Baruch S. Blumberg Institute | Inhibitors of hepatitis B virus covalently closed circular DNA formation and their method of use |
US20190008859A1 (en) | 2015-08-21 | 2019-01-10 | Acerta Pharma B.V. | Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
LU88769I2 (fr) | 1982-07-23 | 1996-11-05 | Zeneca Ltd | Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R)) |
GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
US5395855A (en) | 1990-05-07 | 1995-03-07 | Ciba-Geigy Corporation | Hydrazones |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
TW225528B (es) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
CA2145985C (en) | 1992-10-28 | 2003-09-16 | Napoleone Ferrara | Vascular endothelial cell growth factor antagonists |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
EP2295415A1 (en) | 1995-03-30 | 2011-03-16 | OSI Pharmaceuticals, Inc. | Quinazoline derivatives |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
SI9620103A (sl) | 1995-07-06 | 1998-10-31 | Novartis Ag | Pirolopirimidini in postopki za njihovo pripravo |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
PL190489B1 (pl) | 1996-04-12 | 2005-12-30 | Warner Lambert Co | Nieodwracalne inhibitory kinaz tyrozyny, kompozycja farmaceutyczna je zawierająca i ich zastosowanie |
EP0907642B1 (en) | 1996-06-24 | 2005-11-02 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
WO1998008849A1 (de) | 1996-08-30 | 1998-03-05 | Novartis Aktiengesellschaft | Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens |
CA2264908C (en) | 1996-09-06 | 2006-04-25 | Obducat Ab | Method for anisotropic etching of structures in conducting materials |
DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
CA2265630A1 (en) | 1996-09-13 | 1998-03-19 | Gerald Mcmahon | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
DE59712968D1 (de) | 1996-11-18 | 2008-10-30 | Biotechnolog Forschung Gmbh | Epothilone E und F |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
JP2002504540A (ja) | 1998-02-25 | 2002-02-12 | スローン−ケッタリング インスティトゥート フォア キャンサー リサーチ | エポチロンの合成、その中間体およびそのアナログ |
ATE459616T1 (de) | 1998-08-11 | 2010-03-15 | Novartis Ag | Isochinoline derivate mit angiogenesis-hemmender wirkung |
UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
KR100716272B1 (ko) | 1998-11-20 | 2007-05-09 | 코산 바이오사이언시즈, 인코포레이티드 | 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질 |
DK1140173T4 (da) | 1998-12-22 | 2013-06-10 | Genentech Inc | Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf |
DE60028740T2 (de) | 1999-03-30 | 2007-05-24 | Novartis Ag | Phthalazinderivate zur behandlung von entzündlichen erkrankungen |
PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
WO2005058858A1 (en) * | 2003-12-19 | 2005-06-30 | Biovitrum Ab | Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder |
AU2008206045A1 (en) * | 2007-01-19 | 2008-07-24 | Ardea Biosciences, Inc. | Inhibitors of MEK |
US20110098288A1 (en) * | 2008-03-11 | 2011-04-28 | Jeremy Major | Sulfonamides as zap-70 inhibitors |
-
2010
- 2010-12-07 EA EA201200823A patent/EA201200823A1/ru unknown
- 2010-12-07 CN CN2010800556652A patent/CN102648188A/zh active Pending
- 2010-12-07 WO PCT/EP2010/069099 patent/WO2011070030A1/en active Application Filing
- 2010-12-07 BR BR112012013735A patent/BR112012013735A2/pt not_active IP Right Cessation
- 2010-12-07 US US13/514,208 patent/US8614239B2/en not_active Expired - Fee Related
- 2010-12-07 PE PE2012000778A patent/PE20121384A1/es not_active Application Discontinuation
- 2010-12-07 JP JP2012542525A patent/JP5456908B2/ja not_active Expired - Fee Related
- 2010-12-07 EP EP10790407.0A patent/EP2509964B1/en not_active Not-in-force
- 2010-12-07 MX MX2012006561A patent/MX2012006561A/es not_active Application Discontinuation
- 2010-12-07 CA CA2781218A patent/CA2781218A1/en not_active Abandoned
- 2010-12-07 KR KR1020127017603A patent/KR20120102750A/ko active IP Right Grant
- 2010-12-07 ES ES10790407.0T patent/ES2484171T3/es active Active
- 2010-12-07 GE GEAP201012745A patent/GEP20135998B/en unknown
- 2010-12-07 AU AU2010329940A patent/AU2010329940B2/en not_active Ceased
-
2012
- 2012-05-07 ZA ZA2012/03324A patent/ZA201203324B/en unknown
- 2012-05-07 IL IL219635A patent/IL219635A0/en unknown
- 2012-05-21 TN TNP2012000242A patent/TN2012000242A1/en unknown
- 2012-05-31 CU CU2012000085A patent/CU20120085A7/es unknown
- 2012-06-06 CL CL2012001485A patent/CL2012001485A1/es unknown
- 2012-06-07 NI NI201200100A patent/NI201200100A/es unknown
- 2012-06-07 GT GT201200183A patent/GT201200183A/es unknown
- 2012-06-08 CR CR20120311A patent/CR20120311A/es unknown
- 2012-06-08 DO DO2012000158A patent/DOP2012000158A/es unknown
- 2012-06-12 CO CO12098541A patent/CO6551751A2/es not_active Application Discontinuation
- 2012-06-19 EC ECSP12011984 patent/ECSP12011984A/es unknown
- 2012-06-25 MA MA35003A patent/MA33848B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
US8614239B2 (en) | 2013-12-24 |
EA201200823A1 (ru) | 2013-02-28 |
JP2013512941A (ja) | 2013-04-18 |
NI201200100A (es) | 2012-08-13 |
AU2010329940B2 (en) | 2013-05-16 |
MX2012006561A (es) | 2012-07-04 |
KR20120102750A (ko) | 2012-09-18 |
JP5456908B2 (ja) | 2014-04-02 |
TN2012000242A1 (en) | 2013-12-12 |
WO2011070030A1 (en) | 2011-06-16 |
CN102648188A (zh) | 2012-08-22 |
CU20120085A7 (es) | 2012-10-15 |
AU2010329940A1 (en) | 2012-05-31 |
GT201200183A (es) | 2014-03-27 |
MA33848B1 (fr) | 2012-12-03 |
US20120245209A1 (en) | 2012-09-27 |
IL219635A0 (en) | 2012-07-31 |
EP2509964A1 (en) | 2012-10-17 |
CR20120311A (es) | 2012-10-04 |
ES2484171T3 (es) | 2014-08-11 |
CA2781218A1 (en) | 2011-06-16 |
ECSP12011984A (es) | 2012-07-31 |
PE20121384A1 (es) | 2012-10-13 |
EP2509964B1 (en) | 2014-04-30 |
BR112012013735A2 (pt) | 2019-09-24 |
CL2012001485A1 (es) | 2012-08-03 |
ZA201203324B (en) | 2013-01-30 |
CO6551751A2 (es) | 2012-10-31 |
GEP20135998B (en) | 2013-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP12011878A (es) | Derivados de sulfonamida heterocíclicos útiles como inhibidores de mek | |
CY1124000T1 (el) | Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη | |
CU24099B1 (es) | Derivados de sulfonamida para el tratamiento del dolor | |
CU20180152A7 (es) | Pirimidin-2-ilamino-1h-pirazoles útiles como inhibidores de lrrk2 | |
CL2012001911A1 (es) | Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa. | |
CU20110235A7 (es) | Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17 | |
CO6630162A2 (es) | Derivados del ácido 1-amino -2-ciclopropiletilboronico | |
GT201400031A (es) | Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2 | |
UY33227A (es) | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 | |
CO6491060A2 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
UY32848A (es) | Compuestos heterocíclicos de oxima | |
DOP2012000158A (es) | Derivados de sulfonamida heterociclicos | |
CR20110219A (es) | Ácidos naftilacéticos | |
PA8821301A1 (es) | Inhibidores a base de hidroxamato de desacetilasas b | |
HN2011001019A (es) | Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk) produccion y uso de los mismos como productos medicinales | |
UY35551A (es) | Derivados heteroarilos como inhibidores de aldosterona sintasa | |
CR11759A (es) | Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas | |
UY31775A (es) | Compuestos heterocíclicos como inhibidores de mek | |
UY29814A1 (es) | Derivados nuevos de bencimidazoles y benzotiazoles, su proceso de preparación, su aplicación como medicamentos, composiciones farmacéuticas y utilización nueva principalmente como inhibidores de cmet | |
EA201391820A1 (ru) | Гетероциклические сульфонамидные производные | |
AR086876A1 (es) | Derivados heterociclicos de sulfonamida | |
ECSP088988A (es) | Derivados de ácido fenilacético | |
CU20120067A7 (es) | Derivados de sulfamida heterocíclicos y su uso como inhibidores de mek | |
CU20140021A7 (es) | Derivados de 2- amino-4- (piridin-2-il)-5,6- dihidro-4h-1,3- oxacina y su uso como inhibidores de bace -1 y/o bace-2 | |
CU20100127A7 (es) | Derivados de tiazol usados como inhibidores de pi 3-cinasa |